Navigation Bar

Process to Identify and Obtain Codes for Items Potentially Eligible for
Payment as New Technologies or Transitional Pass-Throughs Under the
Outpatient Prospective Payment System

CPT codes and descriptions only are copyright 1999 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

I. BACKGROUND

We expect to implement a Medicare prospective payment system (PPS) for hospital outpatient services on July 1, 2000. One aspect of the outpatient PPS involves the recognition of new technology items and services as discrete payment groups under the PPS. The PPS will also provide for additional payments to hospitals at amounts higher than the amounts that would otherwise be paid under the PPS for certain drugs, biologicals, and medical devices, as provided for in the transitional pass-through payment provision under section 201(b) of the Balanced Budget Act of 1999 (BBRA). These are temporary payments for a period of 2 to 3 years. Actual hospital cost information gathered during this period will be used to appropriately assign the new technologies and the pass-through items to clinically related payment groups with comparable resource costs in the future.

In this document we describe, below, the process that we will use to (1) identify those items and services potentially eligible for such payments and (2) establish codes for them through the HCFA Common Procedure Coding System (HCPCS) that will be used to initiate payment and process claims for such items.

A large number of the items that may be treated as new technologies or for which payment may be made under the BBRA pass-through provision are already known to us through our own data gathering activities or through comments on the outpatient PPS proposed rule. Many of the items already have HCPCS codes, and we are taking steps to establish temporary codes for the remainder in an orderly fashion. We expect to be able to commence payments for some of these items as either new technologies or pass-throughs when the outpatient PPS is implemented on July 1, 2000 and for others possibly on October 1, 2000. These known items are listed, below, in section VI.

Other items potentially eligible for payment as new technologies or pass-throughs and not listed below are not known to us at this time. Therefore, we ask that interested parties take the steps outlined ,below, in sections III and IV to bring such items to our attention.

II. Potentially Eligible Items

A. New Technology Items and Services. New technology refers to--

1. an item or service that could not have been billed to the Medicare program as a hospital outpatient service in 1996 or, if it was billed in 1996, the costs of the item or service could not have been adequately represented in the 1996 data that we are using to construct the outpatient PPS rates; and,

2. an item or service that is not eligible for payment under the pass-through provision discussed under section II.B, immediately below.

B. Transitional Pass-through Items

Section 201(b) the BBRA 1999 requires us to make additional payments to hospitals for a period of 2 to 3 years for specific items at amounts higher than the amounts that would otherwise be paid under the hospital outpatient prospective payment system. The items designated by the law are the following:

1. Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act

2. Current cancer therapy drugs, biologicals, and brachytherapy devices. These items are those drugs or biologicals that are used in cancer therapy including (but not limited to) chemotherapeutic agents, antiemetics, hematopoietic growth factors, colony stimulating factors, biological response modifiers, bisphosonates, and brachytherapy devices.

3. Current radiolpharmaceutical drugs and biological products used for diagnostic, monitoring, or therapeutic purposes.

4. New drugs, biologicals, or medical devices

In this context, Acurrent@ refers to those items for which hospital outpatient payment is being made on the first date the new PPS is implemented, that is on July 1, 2000. ANew@ refers to an item that was not paid as a hospital outpatient service prior to January 1, 1997 and for which the item=s cost is Anot insignificant@ in relation to the payment for the ambulatory payment classification group (APC) to which it is assigned. The specific criteria regarding the determination of not insignificant will be published in the forthcoming final rule on the hospital outpatient PPS. Until those criteria are published, submit items that meet the date requirement Additionally, new items are those that are not reflected in the 1996 claims data that we are required to use in developing the outpatient PPS.

III. Process for Identifying Items Potentially Eligible for Payment as New Technologies or Pass-Throughs

A manufacturer or other interested party who wishes to bring items that may be eligible for payment as new technologies or under the pass-through provision to our attention should mail their requests for consideration to the following address ONLY:

PPS New Tech/Pass-Throughs, Division of Practitioner and Ambulatory Care
Mailstop C4-03-06
Health Care Financing Administration
7500 Security Boulevard
Baltimore, MD 21244-1850.

To be considered, requests MUST include the following information:

IV. Process for Obtaining HCPCS Codes

We believe some items not yet known to us do not yet have assigned HCPCS codes. We expect to use national HCPCS codes in the hospital outpatient PPS to the greatest extent possible. These codes are established by a well-ordered process that operates on an annual cycle, starting with submission of information by interested parties due by April 1 and leading to announcement of new codes in October of each year.

Considering the exigencies of implementing a new system, we intend to establish temporary codes in 2000 to permit implementation of additional payments for other eligible items effective beginning October 1, 2000. The process for submitting information will be the same as for national codes.

For items that might be candidates for payment as new technologies or pass-throughs but that DO NOT have established HCPCS codes, submit the regular application for a national HCPCS code in accordance with the instructions found on the Internet at http://www.hcfa.gov/medicare/hcpcs.htm. Send applications for national HCPCS codes to --

C. Kaye Riley, HCPCS Coordinator, Health Care Financing Administration
Mailstop C5-08-27
7500 Security Boulevard
Baltimore, Maryland 21244-1850.

V. Deadlines for Submitting Requests

The deadline for submission of applications for a national HCPCS code for the calendar year 2001 cycle is April 1, 2000. The HCPCS process will proceed to assign national codes as warranted, and we expect these codes will be used in the hospital outpatient PPS starting January 1, 2001. Because the coding application will contain information vital to determining a specific item or product=s eligibility for new technology or pass-through payments, we are requesting that a copy of the national HCPCS coding application be sent concurrently to Attention: PPS New Tech/Pass-Throughs, Division of Practitioner and Ambulatory Care at the address specified, above, in section III.

This year, we plan to implement new technology payments and pass-through payments payment for appropriate items on October 1, 2000, if they come to our attention by April 1, 2000. We will use the same submissions made for national HCPCS codes as the basis for making temporary code assignments. A very large volume of requests or systems constraints could affect our ability to fully achieve this goal.

Any applications for HCPCS codes received after April 1, 2000 will be retained for the next cycle of the national HCPCS code assignment process starting April 1, 2001. However, we will also consider these items for assignment of temporary codes that may take effect in January 2001 or in a later quarterly update cycle.

How quickly additional payment for a new item can be implemented will depend on processing and systems constraints; it will in general require at least 6 months and may require as many as 9 months or possibly longer. Thus, for example, a submission that we receive in May (which is too late for October implementation) might get a temporary code to be used for implementing additional payments starting the following January.

Because of staffing and resource limitations, we cannot accept requests by either e-mail or facsimile (FAX) transmission.

VI. List of Known New Technology and Pass-Through Items

As indicated above, we expect to be able to commence payment for some of the new technology or pass-through items identified, below, when the outpatient PPS system is implemented on July 1, 2000 and for others possibly on October 1, 2000. However, we note that we are still evaluating the eligibility of a number of the items listed for payment as either new technologies or pass-through items.

Please note that HCPCS codes for drugs and radiopharmaceuticals listed below reflect the lowest dosages although payment for higher doses will be possible, as will be explained in the forthcoming final rule on the outpatient PPS.

  Medicare Outpatient PPS Requests Received For
  Recognition As New Technology Or Pass-Through
  Payments
   
CPT/HCPCS Description
   
I. Pass-Through Items  
A4642 Satumomab pendetide per dose
A9502 Technetium Tc 99 M tetrofosmin
A9600 Strontium-89 chloride
A9605 Samarium sm 153 lexidronamm
J0130 Abciximab
J0205 Alglucerase injection
J0207 Amifostine
J0256 Alpha 1 proteinase inhibitor
J0286 Amphotericin B lipid complex
J0476 Baclofen intrathecal trial
J0585 Botulinum toxin a per unit
J0640 Leucovorin calcium injection
J0735 Clonidine hydrochloride
J0850 Cytomegalovirus imm IV /vial
J1190 Dexrazoxane HCl injection
J1260 Dolasetron mesylate
J1325 Epoprostenol injection
J1436 Etidronate disodium inj
J1440 Filgrastim 300 mcg injeciton
J1561 Immune globulin 500 mg
J1562 Immune globulin 5 gms
J1565 RSV-ivig
J1620 Gonadorelin hydroch/ 100 mcg
J1626 Granisetron HCl injection
J1745 Infliximab injection
J1785 imiglucerase /unit
J1825 Interferon beta-1a
J1830 Interferon beta-1b / .25 MG
J1950 Leuprolide acetate /3.75 MG
J2275 Morphine sulfate injection
J2352 Octreotide acetate injection
J2355 Oprelvekin injection
J2405 Ondansetron hcl injection
J2430 Pamidronate disodium /30 MG
J2545 Pentamidine isethionte/300mg
J2765 Metoclopramide hcl injection
J2790 Rho d immune globulin inj
J2820 Sargramostim injection
J2994 Retavase
J3010 Fentanyl citrate injeciton
J3280 Thiethylperazine maleate inj
J3305 Inj trimetrexate glucoronate
J7190 Factor viii
J7191 Factor VIII (porcine)
J7192 Factor viii recombinant
J7194 Factor ix complex
J7197 Antithrombin iii injection
J7198 Anti-inhibitor
J7310 Ganciclovir long act implant
J7505 Monoclonal antibodies
J7913 Daclizumab, Parenteral, 25 m
J8510 Oral busulfan
J8520 Capecitabine, oral, 150 mg
J8530 Cyclophosphamide oral 25 MG
J8560 Etoposide oral 50 MG
J8600 Melphalan oral 2 MG
J8610 Methotrexate oral 2.5 MG
J9000 Doxorubic hcl 10 MG vl chemo
J9001 Doxorubicin hcl liposome inj
J9015 Aldesleukin/single use vial
J9020 Asparaginase injection
J9031 Bcg live intravesical vac
J9040 Bleomycin sulfate injection
J9045 Carboplatin injection
J9050 Carmus bischl nitro inj
J9060 Cisplatin 10 MG injeciton
J9065 Cladribine per 1 MG
J9070 Cyclophosphamide 100 MG inj
J9093 Cyclophosphamide lyophilized
J9100 Cytarabine hcl 100 MG inj
J9120 Dactinomycin actinomycin d
J9130 Dacarbazine 10 MG inj
J9150 Daunorubicin
J9151 Daunorubicin citrate liposom
J9165 Diethylstilbestrol injection
J9170 Docetaxel
J9181 Etoposide 10 MG inj
J9185 Fludarabine phosphate inj
J9190 Fluorouracil injection
J9200 Floxuridine injection
J9201 Gemcitabine HCl
J9202 Goserelin acetate implant
J9206 Irinotecan injection
J9208 Ifosfomide injection
J9209 Mesna injection
J9211 Idarubicin hcl injeciton
J9212 Interferon alfacon-1
J9213 Interferon alfa-2a inj
J9214 Interferon alfa-2b inj
J9215 Interferon alfa-n3 inj
J9216 Interferon gamma 1-b inj
J9218 Leuprolide acetate injeciton
J9230 Mechlorethamine hcl inj
J9245 Melphalan hydrochl 50 MG
J9250 Methotrexate sodium inj
J9265 Paclitaxel injection
J9266 Pegaspargase/singl dose vial
J9268 Pentostatin injection
J9270 Plicamycin (mithramycin) inj
J9280 Mitomycin 5 MG inj
J9293 Mitoxantrone hydrochl / 5 MG
J9310 Rituximab
J9320 Streptozocin injection
J9340 Thiotepa injection
J9350 Topotecan
J9355 Trastuzumab
J9357 Valrubicin
J9360 Vinblastine sulfate inj
J9370 Vincristine sulfate 1 MG inj
J9390 Vinorelbine tartrate/10 mg
J9600 Porfimer sodium
Q0136 Non esrd epoetin alpha inj
Q0160 Factor IX non-recombinant
Q0161 Factor IX recombinant
Q0163 Diphenhydramine HCl 50mg
Q0164 Prochlorperazine maleate 5mg
Q0166 Granisetron HCl 1 mg oral
Q0167 Dronabinol 2.5mg oral
Q0169 Promethazine HCl 12.5mg oral
Q0171 Chlorpromazine HCl 10mg oral
Q0173 Trimethobenzamide HCl 250mg
Q0174 Thiethylperazine maleate10mg
Q0175 Perphenazine 4mg oral
Q0177 Hydroxyzine pamoate 25mg
Q0179 Ondansetron HCl 8mg oral
Q0180 Dolasetron mesylate oral
Q0187 Factor viia recombinant
Q2002 Elliot's B solution
Q2003 Aprotinin, 10,000 kiu
Q2004 Treatment for bladder calcul
Q2005 Corticorelin ovine triflutat
Q2006 Digoxin immune FAB (Ovine),
Q2007 Ethanolamine oleate, 1000 ml
Q2008 Fomepizole, 1.5 G
Q2009 Fosphenytoin, 50 mg
Q2010 Glatiramer acetate, 25 mgeny
Q2011 Hemin, 1 mg
Q2012 Pegademase bovine inj 25 I.U
Q2013 Pentastarch 10% inj, 100 ml
Q2014 Sermorelin acetate, 0.5 mg
Q2015 Somatrem, 5 mg
Q2016 Somatropin, 1 mg
Q2017 Teniposide, 50 mg
Q2018 Urofollitropin, 75 I.U.
Q2019 Basiliximab
Q2020 Histrelin Acetate
Q2021 Lepirdin
Q3001 Brachytherapy Seeds
Q3002 Gallium Ga 67
Q3003 Technetium Tc99m Bicisate
Q3004 Xenon Xe 133
   
II. New Technology  
Items  
53850 Prostatic Microwave Thermotx
53852 Prostatic RF Thermotx
78267 Breath Tst Attain/Ciral, C-14
78268 Breath Tst Anaylsis, C-14
G0125 Lung Image (PET)
G0126 Lung Image (PET) Staging
G0163 PET for Rec of Colorectal Ca
G0164 PET for Lymphoma Staging
G0165 PET for Rec of Melanoma/MET Ca
G0166 Extrnl Counterpulse, Per Tx
  NeuroCybernetic Prosthesis System-Vagus Nerve Stimulator

 

Return Arrow Return to the previous page

Last Updated March 9, 2000